Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Type
3.3. Snippet by Application
3.4. Snippet by Route of Administration
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Incidence and Prevalence of Cancer
4.1.1.2. Advancements in Drug Development & Biosimilars
4.1.1.3. XX
4.1.2. Restraints
4.1.2.1. High Cost of Treatment
4.1.2.2. Adverse Side Effects Associated with the Treatment
4.1.2.3. XX
4.1.3. Opportunity
4.1.3.1. Technological Advancements and Combination Therapies
4.1.3.2. XX
4.1.4. Impact Analysis
5. Strategic Insights and Industry Outlook
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established leaders with largest selling Brand
5.1.3. Market leaders with established Product
5.2. CXO Perspectives
5.3. Latest Developments and Breakthroughs
5.4. Case Studies/Ongoing Research
5.5. Regulatory and Reimbursement Landscape
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
5.6. Porter’s Five Forces Analysis
5.7. Supply Chain Analysis
5.8. Patent Analysis
5.9. SWOT Analysis
5.10. Unmet Needs and Gaps
5.11. Recommended Strategies for Market Entry and Expansion
5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
5.13. Pricing Analysis and Price Dynamics
5.14. Key Opinion Leaders
6. By Type
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index By Type
6.2. VEGF-A*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. VEGF-B
6.4. VEGF-C
6.5. VEGF-D
7. By Drug Type
7.1. Introduction
7.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index By Drug Type
7.2. Tyrosine Kinase Inhibitor (TKI)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Pazopanib
7.2.4. Sunitinib Malate
7.2.5. Cabozantinib
7.2.6. Sorafenib
7.2.7. Lenvatinib
7.2.8. Regorafenib
7.2.9. Axitinib
7.2.10. Ponatinib
7.2.11. Tivozanib
7.2.12. Others
7.3. Monoclonal Antibody
7.3.1. Bevacizumab
7.3.2. Brolucizumab
7.3.3. Ramucirumab
7.3.4. Ranibizumab
7.3.5. Faricimab
7.3.6. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index By Application
8.2. Advanced Renal Cell Carcinoma*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Advanced Colorectal Cancer
8.4. Metastatic Colorectal Cancer (mCRC)
8.5. Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
8.6. Recurrent Glioblastoma (rGBM)
8.7. Ovarian Cancer (OC)
8.8. Hepatocellular Carcinoma
8.9. Thyroid cancer
8.10. Non-Small Cell Lung Cancer (NSCLC)
8.11. Wet Age-Related Macular Degeneration (AMD)
8.12. Diabetic Macular Edema (DME)
8.13. Retinal Vein Occlusion (RVO)
8.14. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous
9.4. Intravitreal
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. Latin America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Mexico
10.4.7.2. Brazil
10.4.7.3. Argentina
10.4.7.4. Rest of Latin America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.3.1. Company Revenue’s
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals, etc.
12.1.5. SWOT Analysis
12.2. F. Hoffmann-La Roche Ltd
12.3. Amgen Inc.
12.4. Pfizer Inc.
12.5. Biocon
12.6. Exelixis, Inc.
12.7. Bayer AG
12.8. Eisai Co., Ltd.
12.9. Takeda Pharmaceuticals U.S.A., Inc.
12.10. Sanofi (Regeneron Pharmaceuticals, Inc.)
12.11. AVEO Pharmaceuticals, Inc.
12.12. Eli Lilly and Company
12.13. Genentech USA, Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us